Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07051707 · ClinicalTrials.gov registry record · NA
Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD
A NA study of Chronic Obstructive Pulmonary Disease and COPD, sponsored by Nuvaira.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 6
- Study locations
NCT07051707: Recruiting NA study of Chronic Obstructive Pulmonary Disease and COPD, sponsored by Nuvaira.
NCT07051707 is a NA study of Chronic Obstructive Pulmonary Disease and COPD that is actively recruiting participants, run by Nuvaira. The registered enrollment target is 200 participants, below the 1,752-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (89% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07051707, a NA study of Chronic Obstructive Pulmonary Disease and COPD, is actively recruiting participants, sponsored by Nuvaira.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 6
- Study locations
Study Summary
The dNerva Lung Denervation System is one-time treatment intended to improve breathing in Chronic Obstructive Pulmonary Disease (COPD) patients on standard medical care. The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System in the treatment of COPD.
Primary Outcome
FEV1 will be measured through post bronchodilator (Post-BD) force expiratory volume in 1 second (FEV1) test. Change in FEV1 is defined by a comparison between study arms of the mean change in Post-BD FEV1 based on a linear model for change in Post-BD FEV1 from baseline to 6 months follow-up.
Conditions Studied
Interventions
- DEVICE Targeted Lung Denervation (TLD)
Study Locations (6)
Pennsylvania
- Penn Highlands - Lung Innovations/Clinical Research Associates - DuBois
- Temple University - Temple Lung Center - Philadelphia
- University of Pittsburgh Medical Center - UMPC Comprehensive Lung Center - Pittsburgh
Alabama
- University of Alabama-Birmingham Hospital - UAB Lung Health Center - Birmingham
Michigan
- Henry Ford Hospital - Lung and Pulmonary Care - Detroit
Ohio
- Ohio State University Medical Center - Ohio State Lung Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-02-15 |
| Est. Completion | 2029-10-31 |
| Phase | NA |
What NCT07051707 shows while recruiting
NCT07051707 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,752-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (89% lower).
The record links to 2 conditions, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 1 intervention - of which Targeted Lung Denervation (TLD) is the first listed.
NCT07051707 lists 6 locations in 4 states (Pennsylvania, Alabama, Michigan).
Frequently Asked Questions
What is clinical trial NCT07051707 about?
NCT07051707 is a clinical study titled "Evaluating the Safety and Efficacy of dNerva Lung Denervation System in Patients With COPD". The dNerva Lung Denervation System is one-time treatment intended to improve breathing in Chronic Obstructive Pulmonary Disease (COPD) patients on standard medical care. The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System in the treatment of COPD.
What is the current status of trial NCT07051707?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2026-02-15. Estimated completion is 2029-10-31.
What conditions does trial NCT07051707 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease, COPD.
What interventions are being tested in trial NCT07051707?
The interventions under investigation include: Targeted Lung Denervation (TLD) (DEVICE).
Who is sponsoring clinical trial NCT07051707?
This trial is sponsored by Nuvaira, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07051707 being conducted?
This trial has 6 study locations across Alabama, Michigan, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07051707's enrollment target sits among peer trials
200 38th of 86 higher than 48 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF
RECRUITING · NA
-
Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention
RECRUITING · NA
-
Improving Participation in Pulmonary Rehabilitation Through Peer Support and Storytelling
RECRUITING · NA
-
PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD.
RECRUITING · NA
-
The Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser)
RECRUITING · NA
-
Comprehensive Patient-Centered Home-based Care Coaching for COPD Self-management
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI